AACR logo

More articles from Prostate Cancer

Developmental Programs Are Reactivated in Prostate Cancer Metastasis
Cancer Discovery Oct 2020, 10 (10) OF5; DOI: 10.1158/2159-8290.CD-RW2020-114
Remaining Prostate Luminal Cells Regenerate after Androgen Deprivation
Cancer Discovery Jul 2020, 10 (7) 900; DOI: 10.1158/2159-8290.CD-RW2020-068
DDR-Defective Metastatic Prostate Cancers Are Susceptible to Olaparib
Cancer Discovery Feb 2020, 10 (2) OF11; DOI: 10.1158/2159-8290.CD-RW2019-184
Pembrolizumab Monotherapy Is Active in Metastatic Prostate Cancer
Cancer Discovery Jan 2020, 10 (1) 15; DOI: 10.1158/2159-8290.CD-RW2019-181
Bone-Metastasis Microenvironment May Explain Immunotherapy Resistance
Cancer Discovery Jan 2020, 10 (1) 13; DOI: 10.1158/2159-8290.CD-RW2019-174
Mutations in FOXA1 Cluster into Distinct Structural and Phenotypic Classes
Cancer Discovery Aug 2019, 9 (8) 994; DOI: 10.1158/2159-8290.CD-RW2019-101
Mitochondrial Fission Promotes Prostate Cancer Stem-Cell Self-Renewal
Cancer Discovery Jul 2019, 9 (7) 826; DOI: 10.1158/2159-8290.CD-RW2019-083
Delta-like Protein 3 Is a Target in Neuroendocrine Prostate Cancer
Cancer Discovery May 2019, 9 (5) 577; DOI: 10.1158/2159-8290.CD-RW2019-047
ARv7 Is a Transcriptional Repressor in CRPC
Cancer Discovery Apr 2019, 9 (4) 463; DOI: 10.1158/2159-8290.CD-RW2019-026
ONECUT2 Is a Key Node and Therapeutic Target in Lethal Prostate Cancer
Cancer Discovery Jan 2019, 9 (1) OF12; DOI: 10.1158/2159-8290.CD-RW2018-211

Main menu